Reprint
Personalized and Precision Medicine 2022
Edited by
March 2023
286 pages
- ISBN978-3-0365-7045-7 (Hardback)
- ISBN978-3-0365-7044-0 (PDF)
This book is a reprint of the Special Issue Personalized and Precision Medicine 2022 that was published in
Medicine & Pharmacology
Public Health & Healthcare
Summary
This reprint, guest edited by Anne-Marie Caminade, gives an impressionist overview of the current state of the art about “Personalized and Precision Medicine”. Twenty contributions illustrate the diversity of the topic, including new approaches about cancers, neurodegenerative diseases, infectious diseases, lungs obstruction, skeletal diseases, intestinal microbiomes, new tools such as ultra-high-frequency ultrasound or non-oncological radiotherapy, and a new class of drugs (dendrimers). This reprint is an illustration of the present and future impact of Personalized and Precision Medicine on all the therapeutic domains.
Format
- Hardback
License
© 2022 by the authors; CC BY-NC-ND license
Keywords
cancer treatment; immune checkpoint blockade; PD-(L)1 inhibitors; interorganizational transaction; combination therapy; bacteremia; carbapenemase; carbapenem-resistant Enterobacteriaceae; Klebsiella pneumoniae; mortality; risk factors; bone-anchored maxillary protraction; skeletal class III malocclusion; 3D printing; growth modification; cancer; mucormycosis; COVID-19; COVID-associated mucormycosis; diabetes; steroids; immunosuppression; dendrimers; clinical trials; phases 1, 2, and 3; polylysine; polyamidoamine; TPMT genotype; TPMT poor metabolizers; TPMT intermediate metabolizers; AZA; hepatotoxicity; cumulative incidence of hepatotoxicity; pharmacogenomics; autoimmune disease; preemptive genotyping; TPMI; black elderberry; polyphenols; prebiotic; microbiota; heart rate variability; autonomic nervous system; sleep; obstructive sleep apnea; radiotherapy; non-malignant disorders; non-oncological radiotherapy; electromyography; kinematic; kinetic; low back pain; lumbar belt; sit-to-stand; chronic obstructive pulmonary disease; obstructive sleep apnea; overlap syndrome; vitamin D; ultrasound; ultra-high frequency; musculoskeletal; imaging; urinary bladder neoplasms; neoadjuvant therapy; cystectomy; clinical decision rules; prognosis; multiple sclerosis; personalized medicine; autoimmune; comorbidities; hallmarks of cancer; differential interactome; system biomarkers; druggability; personalized treatments; total knee arthroplasty; fast track rehabilitation; inpatient rehabilitation; postoperative rehabilitation; patient reported outcome measures; Huntington’s disease; psychosocial effects; underserved region; disease burden; genetic counselling; genetic testing; complications; cystectomy; low-molecular-weight heparin; neoadjuvant therapy; thromboembolism; urinary bladder neoplasms; cerebral palsy; muscle spasticity; primary cell culture; satellite cells; skeletal muscle; muscle; skeletal; humans; epigenomics; DNA methylation; regulatory non-coding RNAs; Alzheimer’s disease; logopenic variant primary progressive aphasia; empathy; n/a